Meeting
2023 ASCO Annual Meeting
Optimal molecular-targeted therapies as first-line treatment for RAS wild-type, right-sided metastatic colorectal cancer from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.
Authors
Kentaro Yamazaki
Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan
Kentaro Yamazaki , Yuriko Takeda , Toshihiro Misumi , Motoko Suzuki , Masashi Wakabayashi , Hideaki Bando , Eiji Oki , Jean-Yves Douillard , Cornelis J. A. Punt , Eric Van Cutsem , Carsten Bokemeyer , Alan P. Venook , Yoshihiko Maehara , Volker Heinemann , Chiara Cremolini , Goro Nakayama , Thierry Andre , Qian Shi , Aimery De Gramont , Takayuki Yoshino
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3588)
DOI
10.1200/JCO.2023.41.16_suppl.3588
Abstract #
3588
Poster Bd #
288
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Myostatin/activin pathway gene expression and single nucleotide polymorphisms (SNPs) in metastatic colorectal cancer (mCRC).
First Author: Karam Ashouri
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Real-world use of biologics and its association with outcomes in RAS wild-type (WT) left-sided metastatic colorectal cancer (mCRC) in Canada.
First Author: Winson Y. Cheung
Poster
2017 Gastrointestinal Cancers Symposium
A randomized phase II study to investigate the deepness of response (DpR) of FOLFOXIRI plus cetuximab (Erbitux) versus FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer (mCRC) patients with RAS wild-type tumors: DEEPER.
First Author: Akihito Tsuji
Poster
2017 Gastrointestinal Cancers Symposium
Efficacy of bevacizumab in combination with doublet chemotherapy as first-line therapy in metastatic colorectal cancer according to KRAS status.
First Author: Katsuyuki Murai